A vaccine against SARS-CoV-2 for children and adolescents will play an important role in curbing the COVID-19 pandemic. Here we aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in children and adolescents aged 3–17 years.

Matéria Original

Anterior

CRISPR-Cas System: The Powerful Modulator of Accessory Genomes in Prokaryotes

Próxima

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses